Search
Search
Glenn Jaffe, MD
Show Description +
Glenn J. Jaffe, MD, reviews data from a phase 1 study evaluating the safety of an antisense oligonucleotide designed to reduce complement factor B levels in patients with dry AMD in hopes of reducing the spread of disease. Dr. Jaffe provides an overview complement overactivity, introduces viewers to the science of antisense oligonucleotide drugs, and reviews the safety and efficacy of IONIS-FB-Lrx as seen in a phase 1 trial. He also outlines the structure of a phase 2 study evaluating the safety and efficacy of this drug.
Posted: 5/13/2020
Glenn Jaffe, MD
Glenn J. Jaffe, MD, reviews data from a phase 1 study evaluating the safety of an antisense oligonucleotide designed to reduce complement factor B levels in patients with dry AMD in hopes of reducing the spread of disease. Dr. Jaffe provides an overview complement overactivity, introduces viewers to the science of antisense oligonucleotide drugs, and reviews the safety and efficacy of IONIS-FB-Lrx as seen in a phase 1 trial. He also outlines the structure of a phase 2 study evaluating the safety and efficacy of this drug.
Posted: 5/13/2020
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ARVO: 2020.
Please log in to leave a comment.